MCMingze Chang

Mingze Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mingze Chang has a total of 217 co-authors. Here are the top co-authors by number of shared publications:

  • Hanming Ge

    Department of Neurology, Xi’an No. 3 Hospital The Affiliated Hospital of Northwest University Xi’an China

    9 shared publications
  • Shilin Li

    Department of Neurology, The Affiliated Hospital of Northwest University, Xi’an No.3 hospital, Xi’an, People’s Republic of China

    9 shared publications
  • Gejuan Zhang

    Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, The Affiliated Hospital of Northwest University, Xi'an No. 3 Hospital, Xi'an, Shaanxi, China, xa3yuan.com

    8 shared publications
  • Nannan Han

    Department of Neurology, The Affiliated Hospital of Northwest University, Xi'an No.3 Hospital, Xi'an, Shaanxi, China

    8 shared publications
  • Haojun Ma

    Department of Neurology, The Affiliated Hospital of Northwest University, Xi’an No.3 hospital, Xi’an, People’s Republic of China

    7 shared publications
  • Wenzhen Shi

    Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases The Affiliated Hospital of Northwest University Xi'an China

    7 shared publications

Latest Publications

  • Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial

    by Xinyan Hu, Qianmei Jiang, Ning Wang, Qi Liu, Shilin Li, Pengzhan Wang, Chen Ling, Anxin Wang, Zhe Zhang, Jianying Cao, et al.

    BACKGROUND: Thromboembolism is a common complication after interventional treatment of unruptured intracranial aneurysms. Glycoprotein IIb/IIIa inhibitor tirofiban may reduce thromboembolic complications during neurointerventional therapy for unruptured intracranial aneurysms. We aim to assess the efficacy and safety of prophylactic tirofiban in this clinical setting. METHODS: In this investigator-initiated, phase 2, prospective, randomized, open-label, blinded end point trial (TEAR [Thromboembolic Events in Endovascular Unruptured Aneurysm Repair]), adults aged 18 years to 80 years with unruptured intracranial aneurysms suitable for neurointerventional therapy were enrolled at 2 comprehensive stroke centers in China. Patients were randomly assigned (1:1) to receive intravenous tirofiban combined with dual antiplatelet therapy or dual antiplatelet therapy alone during endovascular aneurysm repair. The primary outcome was the number and volume of new ischemic lesions on diffusion-weighted imaging within 48 hours postprocedure. Key secondary outcomes included the incidence of symptomatic stroke and hemorrhagic events within 48 hours and at 30 days. RESULTS: Between March 2024 and October 2025, 228 patients were screened; we randomly allocated 192 patients to treatment—one individual did not receive magnetic resonance imaging because of intensive care unit hospitalization before imaging; 191 patients were enrolled (95 in the tirofiban group, 96 in the control group). Median age of the patients was 58 years; 22.0% were male, and 78.0% were female. Adjunctive tirofiban significantly reduced the median volume of new infarcts (48.6 versus 88.2 mm 3 , P =0.007) and showed a downward trend in the number of new infarction lesions ( P =0.046). There were no significant differences between groups in symptomatic stroke, intracranial hemorrhage, or major bleeding rates at either 48 hours or 30 days (all P >0.05). CONCLUSIONS: In this randomized, phase 2 trial, prophylactic intravenous tirofiban combined with dual antiplatelet therapy significantly reduced the new postoperative infarct lesions, without increasing hemorrhagic complications and mortality. These findings warrant validation in a multicenter, large-sample trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06238115.

  • Remote Ischemic Postconditioning in Endovascular Thrombectomy for Stroke: The EnTRIPS Randomized Clinical Trial

    by Yawen Cheng, Wanying Chen, Mingze Chang, Xiangning Han, Jia Yu, Meng Wei, Yi Qi, Bo Song, Li Yao, Hua Lv, et al.

    BACKGROUND: Although the neuroprotective potential of remote ischemic postconditioning (RIPC) has been reported, the efficacy and safety of ultra-early RIPC administered after endovascular treatment (EVT) in patients with acute ischemic stroke remain unclear. This study evaluated the efficacy and safety of ultra-early RIPC in patients with acute ischemic stroke undergoing EVT. METHODS: The EnTRIPS trial (Endovascular Treatment Combined with Remote Ischemic Postconditioning in Patients with Acute Ischemic Stroke) was a multicenter, randomized, controlled, outcome assessor-blinded, prospective clinical trial. The trial was conducted at 8 hospitals in China between April 12, 2021, and March 26, 2025. Eligible patients were adults with acute ischemic stroke due to large vessel occlusion who presented within 24 hours of symptom onset, underwent EVT, and achieved successful recanalization. A total of 270 eligible patients were randomized within 6 hours after EVT to receive either RIPC plus guideline-based therapy (n=135) or guideline-based therapy alone (n=135). RIPC was administered for 7 days using pneumatic devices consisting of 5 cycles of bilateral upper-arm cuff inflation (5 minutes at 180 mm Hg) followed by deflation (3 minutes). The primary outcome was functional independence at 90 days, defined as a modified Rankin Scale score of 0 to 2 (range, 0 [no symptoms] to 6 [death]). Safety outcomes included the incidence of RIPC-related adverse events within 7 days. RESULTS: Among 270 randomized patients, a total of 268 (99.3%) participants completed the trial, including 133 in the RIPC group and 135 in the control group (mean [SD] age, 65.5 [16.8] years; 171 [63.8%] men). At 90 days, functional independence was achieved in 81 (60.9%) patients in the RIPC group and 78 (57.8%) patients in the control group (adjusted risk ratio, 1.07 [95% CI, 0.89–1.30]; P =0.46). RIPC-related adverse events occurred in 10 of 133 (7.5%) patients, and no intervention-related adverse events occurred in the control group. CONCLUSIONS: Ultra-early RIPC is safe for patients with acute ischemic stroke treated with EVT, but it does not significantly improve the 90-day functional outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04581759.


  • Open Access

    Fatal Case of Balamuthia Amoebic Encephalitis in a Patient With MOG Antibody-Associated Disease

    by Wang Li, Yan Xudong, Zhang Leshi, Ge Hanming, Li Shilin, Wang Yanfei, Han Nannan, Zhang Gejuan, Chang Mingze

    A 52-year-old female patient with a background of myelin oligodendrocyte glycoprotein antibody-associated disease under immunosuppression presented with headache and confusion, requiring hospitalization. Neurological examination revealed drowsiness, stiff neck, and elevated intracranial pressure in cerebrospinal fluid, accompanied by marked increases in white blood cells and protein levels. The patient experienced convulsions on the first night of admission. MRI identified nodular lesions surrounding edema in bilateral occipital lobes, the posterior horn of the left lateral ventricle, and the left frontal lobe. Within 48 h, the patient progressed to coma and respiratory failure. On the third day, CSF next-generation sequencing confirmed Balamuthia mandrillaris infection. The ornidazole, azithromycin meropenem, vancomycin combined with voriconazole were administered to the patient for anti-infective therapy. Given the severe aggravation of the condition and poor prognosis of the disease, the patient's family requested termination of treatment, and she died a moment later when artificial life support was withdrawn.

  • Open Access

    The predictive value of cerebral blood flow perfusion for cSAH following flow-restricting head and neck artery angioplasty

    by Fangcun Li, Lili Zhao, Wei Huang, Dun Ding, Jialiang Lu, Fan Tang, Fude Liu, Hui Lei, Nannan Han, Ye Li, et al.

    The pathogenesis of convexal subarachnoid haemorrhage (cSAH) remains unclear. Investigating the role of cerebral blood flow (CBF) perfusion in cSAH holds clinical value. We retrospectively reviewed the clinical, laboratory, and preoperative computed tomography perfusion (CTP) or arterial spin labelling data of patients who underwent angioplasty for flow-restricting head and neck artery lesions at four centres (2021–2024). A standardised protocol was used for multi-slice region of interest analysis in watershed regions to calculate the affected/unaffected perfusion ratio. Firth’s penalised-likelihood regression identified independent cSAH risk factors, and model utility was assessed by decision curve analysis. Postoperative cSAH occurred in 41 of 3967 patients (1.0%). Analysis of 111 patients (21 with cSAH, 90 without intracranial haemorrhage [ICH]) revealed that the cSAH group had significantly higher preoperative watershed relative CBF (rCBF) in global anterior, posterior, and overall regions (all P < 0.05). Multivariable analysis identified preoperative watershed rCBF ≥ 1.1 (odds ratio [OR] 9.20, 95% confidence interval [CI] 2.58–40.23; P < 0.001) and prolonged prothrombin time (PT) (OR 3.21, 95% CI 1.69–7.44; P < 0.001) as independent risk factors. Higher mean platelet volume (MPV) was protective (OR 0.47, 95% CI 0.20–0.99; P = 0.046). The prediction model (corrected area under the curve 0.882) provided net clinical benefit. cSAH did not affect 90-day outcomes (P = 0.198). Following flow-restricting angioplasty, the cSAH rate was approximately 1%. Preoperative watershed hyperperfusion was a key predictor. Prolonged PT increased cSAH risk, whereas elevated MPV was protective. With appropriate management, cSAH may not worsen prognosis. The online version contains supplementary material available at 10.1186/s12883-026-04883-9.

  • Open Access

    Systemic Inflammation Mediates the Association Between Admission Hyperglycemia and Pulmonary Infection or Prognosis in Acute Ischemic Stroke

    by Xiaojuan Ma, Jinwei Duan, Ye Cheng, Wu Li, Chen Liang, Tian Yang, Jie Liu, Yan Mi, Shan Du, Feixiao Xue, et al.

    Background and Perspectives: Hyperglycemia frequently occurs after the onset of acute ischemic stroke (AIS) and the distinct effects and mechanisms of long‐term or transient hyperglycemia on stroke outcome are incompletely revealed. We aimed to investigate the potential mediating role of systemic inflammation in admission glycemia status with clinical outcome. Methods: A total of 2233 eligible AIS patients were enrolled from January 2018 to February 2024 and followed up for 12 months. Patients were stratified into three groups: normoglycemia (NG, n = 1341), persistent hyperglycemia (PHG, n = 588) and stress‐induced transient hyperglycemia (SIH, n = 304). Systemic immune‐inflammation index (SII), systemic inflammation response index (SIRI) were calculated from baseline blood cell counts. The primary outcomes were in‐hospital stroke‐associated pneumonia (SAP) and poor functional outcome (modified Rankin Scale [mRS] >2) at 12 months. Results: Among the included patients, 26.3% had PHG and 13.6% developed SIH. The rates of SAP and poor prognosis were highest in SIH group, intermediate in the PHG group and lowest in the NG group. Patients in SIH group exhibited highest systemic inflammatory levels (C‐reactive protein [CRP], hsCRP, lnSII, SIRI, and neutrophil‐to‐lymphocyte [NLR]). After adjusting for confounders identified by LASSO regression, both tertile 3 of lnSII and SIRI were significantly associated with higher risk of SAP independent of admission glycemia status. While higher lnSII and SIRI were significantly associated with poor prognosis at 12‐month only in SIH group. Mediation analysis demonstrated that lnSII partially mediated the association between glycemic status and clinical outcomes (mediation proportion: 16.7% for SAP; 10.8% for prognosis), with a similar effect observed for SIRI. The prediction model incorporating clinical variables and lnSII or SIRI yielded an AUC around 0.90 for SAP and 0.84 for 12‐month prognosis. Conclusion: Admission hyperglycemia, particularly SIH, notably affected the incidence of SAP and poor prognosis. Systemic inflammation partially mediated the effect of hyperglycemia on clinical outcome in AIS.


  • Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT

    by Feng Gao, Xu Tong, Ming Wei, Xiaoxi Yao, Lei Li, Yuesong Pan, Baixue Jia, Thanh N. Nguyen, Ming Yang, Dapeng Sun, et al.

    BACKGROUND: The long-term benefits of bailout intracranial angioplasty or stenting (BAOS) after thrombectomy in patients with acute large vessel occlusion remain unclear. This study compared BAOS with standard therapy in patients with large vessel occlusion with unsuccessful recanalization (expanded Thrombolysis In Cerebral Infarction score 0–2a) or >70% residual stenosis after thrombectomy. METHODS: ANGEL-REBOOT (Randomized Study of Bailout Intracranial Angioplasty Following Thrombectomy for Acute Large Vessel Occlusion) was a multicenter, open-label, blinded–end point, randomized trial conducted across 36 Chinese hospitals. Patients ≥18 years of age with anterior or posterior circulation large vessel occlusion within 24 hours of stroke onset were enrolled. After identification of thrombectomy failure or high-grade residual stenosis, patients were randomly assigned to the BAOS group (intervention) or the standard therapy group (control), in which thrombectomy was continued or terminated. The use of tirofiban was permitted in both groups during and after the procedure. In the intention-to-treat population, the primary outcome was analyzed using an assumption-free ordinal analysis (Wilcoxon-Mann-Whitney test) to compare the modified Rankin Scale scores (ordinal variable ranging from 0 to 6) between groups at 1-year follow-up, from which the generalized odds ratio was derived. Secondary outcomes included stroke recurrence in the treated artery and all-cause mortality within 1 year, analyzed using Cox proportional hazards models. RESULTS: A total of 348 patients were randomly assigned (176 to the BAOS group and 172 to the standard therapy group) and followed for 90 days, from December 19, 2021, to June 2, 2023. Of these, 326 patients (166 in the BAOS group and 160 in the standard therapy group) completed the 1-year follow-up. Compared with standard therapy, BAOS significantly improved the 1-year modified Rankin Scale score distribution (generalized odds ratio, 1.34 [95% CI, 1.05–1.73]; P =0.02). Fewer stroke recurrences in the treated artery occurred in the BAOS group than in the standard therapy group (7 of 166 [4%] versus 21 of 160 [13%]; hazard ratio, 0.30 [95% CI, 0.13–0.71]; P =0.006). One-year mortality rates were similar between groups (25 of 166 [15%] versus 27 of 160 [17%]; hazard ratio, 0.87 [95% CI, 0.50–1.50]). CONCLUSIONS: Among Chinese patients with large vessel occlusion with unsuccessful recanalization or high-grade residual stenosis after thrombectomy, BAOS was associated with reduced disability and stroke recurrence after 1 year compared with standard therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05122286.


  • Predicting early severe midline shift in acute ischemic stroke Within 24 h of endovascular thrombectomy

    by Nannan Han, Xiaobo Zhang, Yu Zhang, Leshi Zhang, Haojun Ma, Tengfei Li, Xudong Yan, Zhi Chen, Ying Lu, Song Wang, et al.

    Purpose Early and severe (ES) midline shift (MLS ≥ 10 mm) simultaneously occurring within 24 h after endovascular thrombectomy (EVT) is a life-threatening emergency that requires immediate intervention. This study aims to describe ES-MLS and develop a predictive model in patients with anterior circulation occlusion who have undergone EVT. Methods This retrospective cohort study utilized data from a prospective registry. Functional outcome was defined as a modified Rankin Scale score of 0–2. Radiomic features extracted from pre-EVT diffusion-weighted imaging were subjected to LASSO regression with fourfold cross-validation. Clinical features were selected via multivariable regression and integrated into a nomogram, with performance evaluated through receiver operating characteristic curve analysis in both training and validation datasets. Results A total of 481 patients (median age 68 [IQR 58–76], 39.7% female) were included in this study, which consisted of a training dataset (n = 361) and a validation dataset (n = 120). In the ES-MLS group, 85.7% had died and none had a functional outcome at the 90-day follow-up. Recanalization, NIHSS score, and two radiomic features were identified as factors associated with ES-MLS in the nomogram. The predictive model exhibited an area under the curve (AUC) of 0.844 (95% confidence interval [CI], 0.803–0.880) in the training dataset and 0.823 (95% CI, 0.743–0.887) in the validation dataset. Conclusion This is the initial structured overview of ES-MLS after EVT, featuring a model designed for personalized prediction of ES-MLS. The tool may enhance patient selection before EVT and refine the aggressive monitoring strategy after EVT.

  • Open Access

    Dopamine D4 receptors in the lateral habenula regulate anxiety-related behaviors in a rat model of Parkinson's disease

    by Chengxue Du, Jiachen Wang, Huihui Tan, Nannan Han, Xiaobo Li, Baihua Sun, Gejuan Zhang, Mingze Chang


  • Open Access

    Effect of Intravenous Tirofiban Versus Placebo on First‐Pass Successful Reperfusion in Endovascular Stroke Thrombectomy: Insights From the RESCUE BT Randomized Clinical Trial

    by Junjie Yuan, Hanming Ge, Zhaojun Tao, Huijie An, Qin Han, Jeffrey L. Saver, Thanh N. Nguyen, Simin Zhou, An Mao, Yuelu Wu, et al.

    Background: First‐pass successful reperfusion (FPSR), defined as a successful/complete reperfusion achieved after a single thrombectomy pass, is predictive of favorable outcome in patients with acute ischemic stroke with large‐vessel occlusion. It is unknown whether intravenous tirofiban is effective in increasing the rate of FPSR in acute anterior large‐vessel occlusion stroke. Methods and Results: Patients who had acute large‐vessel occlusion stroke presenting within 24 hours and underwent endovascular thrombectomy were analyzed from the RESCUE BT (Intravenous Tirofiban for Patients With Large Vessel Occlusion Stroke) clinical trial, of which the main analysis was neutral. The RESCUE BT trial randomized patients to receive either intravenous tirofiban or placebo before endovascular thrombectomy. The primary end point was FPSR, defined as successful reperfusion (extended thrombolysis in cerebral infarction scale 2b50, 2c, or 3) at first thrombectomy attempt. A modified Poisson regression analysis assessed the association between intravenous tirofiban treatment and FPSR. Of 948 enrolled patients, 463 patients were randomized to the tirofiban group and 485 to the placebo group. The mean age was 67 years, and 41.0% of the patients were women. FPSR was achieved more often in the tirofiban group (30.5% versus 23.5%; adjusted risk ratio, 1.24 [95% CI, 1.01–1.51]; P =0.04). FPSR was associated with a favorable shift to lower modified Rankin Scale disability levels at 90 days (common odds ratio, 1.42 [95% CI, 1.08–1.86]; P =0.01). Conclusions: In this post hoc analysis of the RESCUE BT trial, treatment with intravenous tirofiban before endovascular thrombectomy was associated with increased FPSR in patients with acute ischemic stroke due to large‐vessel occlusion in the anterior circulation. FPSR was associated with reduced 90‐day levels of disability. Registration: URL: http://chictr.org ; Unique Identifier: ChiCTR‐INR‐17014167.